Menu

Experience

Charles Bair

    • Bristol Myers Squibb to Acquire Turning Point Therapeutics for $4.1 Billion 


    • Kronos Bio – $288 million IPO 


    • Turning Point Therapeutics - $192 Million IPO 


    • Allogene Therapeutics – $372.6 Million IPO 


    • Cidara Completes Initial Public Offering  


    • Sientra Completes $75 Million Initial Public Offering 


    • Ambit Biosciences to be Acquired by Daiichi Sankyo for $410 Million 


    • Kite Pharma $146 Million Initial Public Offering 


    • Trius Therapeutics Acquisition by Cubist Pharmaceuticals 


    • Measurabl Series A and Series B Financings